Palatin Technologies (NYSEAMERICAN:PTN – Get Free Report) is expected to be announcing its Q3 2025 earnings results before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of ($0.17) per share for the quarter.
Palatin Technologies Trading Down 43.8%
PTN opened at $0.10 on Monday. The stock has a 50-day moving average price of $0.39 and a 200-day moving average price of $0.87. Palatin Technologies has a 12-month low of $0.09 and a 12-month high of $2.13. The stock has a market capitalization of $2.49 million, a P/E ratio of -0.06 and a beta of 0.87.
Analyst Ratings Changes
Separately, HC Wainwright lowered their price target on shares of Palatin Technologies from $17.00 to $7.00 and set a “buy” rating for the company in a research note on Thursday, February 13th.
Palatin Technologies Company Profile
Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.
Read More
- Five stocks we like better than Palatin Technologies
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Nextracker’s Solar Surge: Will It Shatter Its All-Time High?
- Ride Out The Recession With These Dividend Kings
- Savvy Investors Are Raising a Glass for Heineken Stock
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Top 4 ETFs for China Exposure After Tariff Relief
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
